YHB Investment Advisors Inc. increased its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 4.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 98,173 shares of the medical research company’s stock after purchasing an additional 4,133 shares during the period. Thermo Fisher Scientific accounts for about 3.3% of YHB Investment Advisors Inc.’s holdings, making the stock its 3rd biggest holding. YHB Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $18,574,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in TMO. L & S Advisors Inc boosted its position in Thermo Fisher Scientific by 126.5% during the 1st quarter. L & S Advisors Inc now owns 3,670 shares of the medical research company’s stock worth $564,000 after purchasing an additional 2,050 shares during the period. Pictet & Cie Europe SA boosted its position in Thermo Fisher Scientific by 1.8% during the 1st quarter. Pictet & Cie Europe SA now owns 88,003 shares of the medical research company’s stock worth $13,517,000 after purchasing an additional 1,550 shares during the period. Pictet North America Advisors SA purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth $264,000. Princeton Portfolio Strategies Group LLC boosted its position in Thermo Fisher Scientific by 1.6% during the 1st quarter. Princeton Portfolio Strategies Group LLC now owns 36,835 shares of the medical research company’s stock worth $5,658,000 after purchasing an additional 575 shares during the period. Finally, Thrivent Financial For Lutherans boosted its position in Thermo Fisher Scientific by 4.1% during the 1st quarter. Thrivent Financial For Lutherans now owns 14,330 shares of the medical research company’s stock worth $2,201,000 after purchasing an additional 570 shares during the period. 86.18% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently weighed in on TMO shares. Leerink Swann upped their price target on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research report on Monday, October 9th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price target for the company in a research report on Thursday, September 21st. Cowen reissued an “outperform” rating and issued a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Finally, Barclays reissued an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and a consensus price target of $205.71.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded down $0.56 during trading on Friday, hitting $192.20. 1,335,426 shares of the stock were exchanged, compared to its average volume of 1,336,481. The firm has a market cap of $77,297.88, a price-to-earnings ratio of 21.18, a PEG ratio of 1.76 and a beta of 1.07. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc has a 1-year low of $139.32 and a 1-year high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.03 EPS. equities analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

In other news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the sale, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The disclosure for this sale can be found here. Corporate insiders own 0.49% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/02/thermo-fisher-scientific-inc-tmo-position-increased-by-yhb-investment-advisors-inc.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.